

## Bullous cutaneous larva migrans

A 34-year-old man developed a blister with itching and migrating serpiginous tracts on both feet [Figure 1a, 1b] over 7 days after playing volleyball barefoot on a beach in California. He was diagnosed with bullous cutaneous larva migrans and treated with albendazole (400 mg daily for 3 days), ivermectin (12 mg stat) and prednisolone (10 mg once daily for 3 days and tapered to 5 mg for the next 3 days).

His cutaneous larva migrans was resolved within a week. Cutaneous larva migrans, caused by animal hookworm larvae, can occasionally present with vesicles and bullae. The exact mechanism of bulla formation is unclear but may involve hypersensitivity or larval lytic enzymes. Due to rising helminthic resistance, dual therapy with albendazole and ivermectin is becoming increasingly necessary.



**Figure 1a-b:** Erythematous, serpiginous tracts with tense bullae suggestive of bullous cutaneous larva migrans over both feet.

**Declaration of patient consent:** The authors certify that they have obtained all appropriate patient consent.

**Financial support and sponsorship:** Nil.

**Conflicts of interest:** There are no conflicts of interest.

**Use of artificial intelligence (AI)-assisted technology for manuscript preparation:** The author confirms that there was no use of artificial intelligence (AI)-assisted technology for assisting in the writing or editing of the manuscript and no images were manipulated using AI.

**Yashika Jayesh Doshi<sup>1</sup>**

<sup>1</sup>Department of Dermatology, Venereology and Leprosy,  
B. J. Medical College and Civil Hospital,  
Ahmedabad, Gujarat, India

**Corresponding author:**

Dr. Yashika Jayesh Doshi,  
Department of Dermatology, Venereology and Leprosy,  
B. J. Medical College and Civil Hospital,  
Ahmedabad, Gujarat, India.  
yashikajdoshi@gmail.com

**How to cite this article:** Doshi YJ. Bullous cutaneous larva migrans. Indian J Dermatol Venereol Leprol. doi: 10.25259/IJDVL\_373\_2025

**Received:** March, 2025 **Accepted:** March, 2025 **Epub Ahead of Print:** May, 2025

**DOI:** 10.25259/IJDVL\_373\_2025

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, transform, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.